Drug Trial Radar · NCT04999527
Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jul 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Aug 10, 2021
Primary completion
Jun 30, 2022
Study completion Jun 30, 2022
Sponsor
- Lead sponsor
- Disc Medicine, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult healthy volunteers.
Conditions
- Healthy Volunteer
Interventions
DISC-0974Drug
DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
PlaceboDrug
Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Up to 71 days of monitoring
- Incidence of abnormal laboratory test resultsTime frame: Up to 71 days of monitoring
- Incidence of treatment-emergent clinically abnormal electrocardiogram (ECG)Time frame: Up to 71 days of monitoring
- Incidence of treatment-emergent clinically abnormal physical examTime frame: Up to 71 days of monitoring
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Worldwide Clinical Trials
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.